SPECTRUM

• The change of BCVA from baseline to 12 months as evaluated in routine clinical practice

_{BCVA measurements at baseline (first injection of aflibercept 8 mg) and at 12 months as ETDRS letters (according to the ETDRS chart or other methods (e.g. Snellen charts) used in the routine clinical practice in participating countries or sites (with conversion to ETDRS))}

_{Time Frame: At baseline and 12 months}

• The change of BCVA from baseline to 4 weeks, 8 weeks, 6 months, and 24 months as evaluated in routine clinical practice

_{Time Frame: At baseline, 4 weeks, 8 weeks, 6 months and 24 months}

• Number of aflibercept 8 mg injections in the study eye during the first 6 months, the first year (12 months), the second year (24 months), and the entire observation period (last visit), respectively

_{Performed intravitreal aflibercept 8 mg injections in study eye (including date)}

_{Time Frame: At baseline, 4 weeks, 8 weeks, 6 months and 24 months}

• Number of visits regarding the study eye by type of visit during the first 6 months, the first 12 months, and the 24 months treatment period

_{Performed different type of visits for study eye}

_{Time Frame: Up to 24 months}

• Number of treated study eyes with 5, 10, and 15 letters (or equivalent) BCVA gain/loss from baseline at 4 weeks, 8 weeks, 6, 12, and 24 months

_{Time Frame: At baseline, 4 weeks, 8 weeks, 6 months and 24 months}

• Change in central retinal thickness as measured by optical coherence tomography (OCT) from baseline to 4 weeks, 8 weeks, 6, 12, and 24 month follow up

_{Time Frame: At baseline, 4 weeks, 8 weeks, 6 months and 24 months}

• Number of participants with (serious) adverse events and (serious) drug-related adverse events

_{Time Frame: From the first application of aflibercept 8 mg up to 24 months}

Inclusion criteria for patients with nAMD

• A diagnosis of nAMD

• Patient aged ≥50 years

• Patients for whom the decision to IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice

• Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Inclusion criteria for patients with DME

• A diagnosis of DME

• Patient aged ≥18 years (or country’s legal age of adulthood if the legal age is >18 years) with type 1 or type 2 diabetes mellitus

• Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice

• Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Exclusion criteria for all patients with nAMD

• Participation in an investigational program with interventions outside of clinical routine practice

• Contraindications as listed in the local intravitreal aflibercept 8 mg local product information

• Extra/periocular infection or inflammation in either eye at time of first injection

• Patient receiving other intravitreal treatments other than aflibercept in the fellow eye

• Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information
 

Additional exclusion criteria for treatment-naïve patients with nAMD

• Any prior ocular treatment in the study eye or systemic treatment in nAMD

Additional exclusion criteria for pretreated patients with nAMD

• Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days

• Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months

• Fluocinolone implant in the study eye within the last 3 years

• Dexamethasone implant in the study eye within the last 6 months

• Any concurrent drug releasing implant in the study eye

Exclusion criteria for all patients with DME

• Participation in an investigational program with interventions outside of clinical routine practice

• Contraindications as listed in the intravitreal aflibercept 8 mg local product information

• Extra/periocular infection or inflammation in either eye at time of first injection

• Patient receiving other intravitreal treatments other than aflibercept in the fellow eye

• Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information

• Previous treatment of the study eye with laser in the last 90 days prior to first IVT aflibercept 8 mg
 

Additional exclusion criteria for treatment-naïve patients with DME

• Any prior ocular treatment in the study eye or systemic treatment in DME
 

Additional exclusion criteria for pretreated patients with DME

• Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days

• Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months

• Fluocinolone implant in the study eye within the last 3 years

• Dexamethasone implant in the study eye within the last 6 months

• Any concurrent drug releasing implant in the study eye